Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novonesis (Novozymes) BNVZMY +0.92%91 EV-to-EBIT is 36.75 as of Aug. 27, 2026, which is 41% above its 10-year median of 26.02. GuruFocus rates NVZMY with a GF Score™ of 91/100 and a GF Value™ of $65.00 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,274 Chemicals companies, Novonesis (Novozymes) B ranks worse than 77.55% on this metric.
Novonesis (Novozymes) B (OTCPK:NVZMY) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Novonesis (Novozymes) B's Enterprise Value for the quarter that ended in Jun. 2026 was $32,659 Mil.
Novonesis (Novozymes) B's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $988 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novonesis (Novozymes) B EV-to-EBIT Related Terms
Novonesis (Novozymes) B EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novonesis (Novozymes) B EV-to-EBIT vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Novonesis (Novozymes) B's EV-to-EBIT falls into.
Novonesis (Novozymes) B's current Enterprise Value is $36,318 Mil.
Novonesis (Novozymes) B's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $988 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novonesis (Novozymes) B (NVZMY) has a EV-to-EBIT of 36.75 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Novonesis (Novozymes) B and its competitors. This is 41% above median its historical median of 26.02. Over the past decade, Novonesis (Novozymes) B's EV-to-EBIT has ranged from 17.35 to 63.88. According to the industry distribution chart, Novonesis (Novozymes) B ranks #988 out of 1274 companies in the Chemicals industry, placing it in the top 77.6%.
Is Novonesis (Novozymes) B's EV-to-EBIT too high?
Novonesis (Novozymes) B's current EV-to-EBIT of 36.75 is 41% above median its 10-year median of 26.02. Over the past 10 years, this metric has ranged from a low of 17.35 to a high of 63.88. The Chemicals industry median EV-to-EBIT is 16.69. Novonesis (Novozymes) B's value of 36.75 is 120.3% above this industry median. Based on the distribution chart, Novonesis (Novozymes) B ranks #988 out of 1274 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Novonesis (Novozymes) B has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's EV-to-EBIT compare to LIN and SHW?
According to the Chemicals industry distribution chart, Novonesis (Novozymes) B ranks #988 out of 1274 companies for EV-to-EBIT. This places Novonesis (Novozymes) B in the lower half of its industry. The industry median EV-to-EBIT is 16.69. Novonesis (Novozymes) B's value of 36.75 is 120.3% above this benchmark. Historically, Novonesis (Novozymes) B's own EV-to-EBIT has ranged from 17.35 to 63.88 over the past decade. While the company's 10-year median is 26.02 vs. the industry median of 16.69, Novonesis (Novozymes) B has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Chemicals company?
The median EV-to-EBIT among Chemicals companies is 16.69, based on 1,274 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novonesis (Novozymes) B's current EV-to-EBIT of 36.75 is 120.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Novonesis (Novozymes) B and its competitors. For the Chemicals industry, the median EV-to-EBIT is 16.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novonesis (Novozymes) B's current EV-to-EBIT is 36.75, which is 41% above median its own 10-year median of 26.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (NVZMY) is currently considered Fairly Valued. The stock's GF Value™ is $65.00, compared to a current price of $71.00 — trading 9.2% above its estimated fair value. The current EV-to-EBIT is 36.75, which is 41% above median its 10-year median of 26.02 and 120.3% above the Chemicals industry median of 16.69. Novonesis (Novozymes) B's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Novonesis (Novozymes) B (NVZMY), the current EV-to-EBIT is 36.75 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novonesis (Novozymes) B (NVZMY) Overvalued in 2026?
Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued.
The current stock price of $71.00 is trading 9.2% above its estimated GF Value™ of $65.00.
GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.
Key valuation signals for NVZMY:
EV-to-EBIT: 36.75 (41% above median its 10-year median of 26.02)
GF Value™: $65.00 vs. price of $71.00 (9.2% above fair value)
Industry Position: 120.3% above the Chemicals median (#988 of 1274)
No single metric tells the full story. See the NVZMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
91GF Score
Get the complete analysis for NVZMY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVZMY has been successfully added to your 
